Systimmune

SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026

Fairbanks Daily News-Miner · 7 days ago

SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026

Fontana Herald News · 7 days ago

SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026

PR Newswire · 7 days ago

ABL Bio partner Systimmune reports 100% complete remission in lymphoma drug combo trial

mbiz.heraldcorp.com · 22 days ago

SystImmune doses first patient in Phase III trial for ES-SCLC

Yahoo · about 1 month ago

SystImmune doses first patient in Phase III trial for ES-SCLC

Yahoo · about 1 month ago

SystImmune doses first patient in Phase III trial for ES-SCLC

Clinical Trials Arena · about 1 month ago

SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer

Yahoo Finance · about 2 months ago

SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer

PR Newswire · about 2 months ago

SystImmune's iza-bren wins China approval for esophageal...

AllSci · 2 months ago

SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

goSkagit · 2 months ago

SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

BioSpace · 2 months ago

SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Morningstar · 2 months ago

SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

PR Newswire · 2 months ago

SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China

BioSpace · 3 months ago

SystImmune, Biokin secure first China approval for bispecific ADC iza-bren

BioSpectrum Asia · 3 months ago

Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies

Yahoo Finance · 3 months ago

SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China

PR Newswire · 3 months ago

Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate

PMLiVE · 4 months ago

SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO

PR Newswire · 4 months ago